Evaluation of Biological Activity Exerted by an Aza-Bicyclocarboxylic Acid Derivative Using an Ischemia-Reperfusion Injury Model

    December 2018 in “ Biomedical and pharmacology journal/Biomedical & pharmacology journal ”
    Lauro Figueroa‐Valverde, Rosas‐Nexticapa Marcela, Mateu‐Armand Virginia, Socorro Mesa, Francisco Díaz-Cedillo, García-Cervera Elodia, Pool-Gómez Eduardo, Rolando R. García, Cauich-Carrillo Regina, Euan-Hau Saidy, Parra-Galindo Perla
    TLDR Compound 3 protects the heart from damage by activating A1-adenosine receptors.
    The study evaluated the cardioprotective effects of an aza-bicyclocarboxylic acid derivative (compound 3) against ischemia-reperfusion injury in male Wistar rats (n = 9 per group). Compound 3 significantly decreased infarct size in a dose-dependent manner, similar to adenosine, but this effect was blocked by rolofylline. It also decreased cAMP levels over time. The findings suggested that compound 3 produced a cardioprotective effect by activating A1-adenosine receptors, leading to changes in cAMP levels. Comparisons with other drugs indicated that compound 3 had a unique and significant effect on reducing infarct size, confirmed by histological evaluations and robust data from 9 experiments per condition.
    Discuss this study in the Community →